Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Oct 06, 2020 8:45 AM - Oct 08, 2020 1:00 PM

(Central Europe Standard Time)

4051 Basel, Switzerland

Global Forum for Qualified Persons for Pharmacovigilance (QPPV)

Session 2: Business Partners Oversight

Session Chair(s)

Shahinaz  Badr, PHARMD

Shahinaz Badr, PHARMD

Founder & Managing Director, Vigilance Gate FZ,LLC, United Arab Emirates

Gemma  Jimenez Sese

Gemma Jimenez Sese

Senior Director, Deputy EU QPPV, AstraZeneca, Spain

NO SIZE FITS ALL: Mergers, acquisitions, joint ventures, Co-marketing, Co-Promotion or just distribution deals, are different business models for which QPPV is expected to have oversight whether in EU or outside EU regardless whether you are from a big or small company. This session will cover key aspects regarding business partners, from due diligence activities, establishment the appropriate PV agreements or KPIs to how to maximise PSMF use.

Speaker(s)

Vicki  Edwards, RPH

Vicki Edwards, RPH

Vice President, Pharmacovigilance Excellence and International QPPV, Abbvie, United Kingdom

In case of mergers and acquisitions, joint venture … etc : examples of two of big pharma different corporate restructuring and the impact on the oversight starting with the due diligence and structuring of the SDEA

Willemijn  van der Spuij, MSC

Willemijn van der Spuij, MSC

Executive Director Europe | International - Patient Safety, Bristol Myers Squibb, Switzerland

In case of mergers and acquisitions, joint venture … etc : examples of two of big pharma different corporate restructuring and the impact on the oversight starting with the due diligence and structuring of the SDEA

Elspeth  McIntosh, MBA, RN

Elspeth McIntosh, MBA, RN

Director, Castle Pharmacovigilance Ltd, United Kingdom

Outsourcing and extended role of the EU QPPV which may not involve the integration of other PV systems into the company’s PV system but oversight as it is a different PV system: Small pharma example here with the EX-EU QPPV, different PSMF

Shahinaz  Badr, PHARMD

Shahinaz Badr, PHARMD

Founder & Managing Director, Vigilance Gate FZ,LLC, United Arab Emirates

Challenges Met to Keep the Oversight in Terms of Legislations Changes

Gemma  Jimenez Sese

Gemma Jimenez Sese

Senior Director, Deputy EU QPPV, AstraZeneca, Spain

Challenges Met to Keep the Oversight in Terms of Legislations Changes

Dionne  Usher

Dionne Usher

Associate Director, Office of the EU QPPV, Merck Sharp & Dohme Limited, United Kingdom

Challenges met in the PSMF, PSSF or different PSMFs involved, and how far can we go with auditing

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.